ADC Therapeutics (ADCT) Change in Cash (2019 - 2026)
ADC Therapeutics has reported Change in Cash over the past 8 years, most recently at -$30.3 million for Q1 2026.
- Quarterly results put Change in Cash at -$30.3 million for Q1 2026, up 46.16% from a year ago — trailing twelve months through Mar 2026 was $36.2 million (up 191.09% YoY), and the annual figure for FY2025 was $10.2 million, up 136.77%.
- Change in Cash reached -$30.3 million in Q1 2026 per ADCT's latest filing, down from $26.6 million in the prior quarter.
- Across five years, Change in Cash topped out at $69.7 million in Q2 2025 and bottomed at -$139.8 million in Q4 2022.
- Median Change in Cash over the past 5 years was -$23.1 million (2024), compared with a mean of -$13.9 million.
- Peak annual rise in Change in Cash hit 68499.1% in 2023, while the deepest fall reached 859017.79% in 2023.
- Over 5 years, Change in Cash stood at -$139.8 million in 2022, then skyrocketed by 77.14% to -$32.0 million in 2023, then rose by 27.84% to -$23.1 million in 2024, then skyrocketed by 215.45% to $26.6 million in 2025, then plummeted by 213.9% to -$30.3 million in 2026.
- Business Quant data shows Change in Cash for ADCT at -$30.3 million in Q1 2026, $26.6 million in Q4 2025, and -$29.8 million in Q3 2025.